The Central Social Insurance Medical Council, better known as Chuikyo, appears to see the need to set up new dosage…
HOME > REGULATORY
REGULATORY
- Japan-China Pharma Regulators to Start 4 Projects to Boost Cooperation
September 12, 2011
- MHLW Designates 6 Products Including ruxolitinib as Orphan Drugs
September 9, 2011
- Medical Costs Reduced ¥7 Bil. by Promoting Use of GEs: JHIA
September 9, 2011
- MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
- Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
- CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 8, 2011
- Generic Dispensing Not Promoted in Pharmacies: CSIMC’s Subcommittee
September 8, 2011
- CSIMC Introduces New Rule for Pricing of High-Priced Drugs; 10 Drugs to Be Reimbursed on Piecework under DPC
September 8, 2011
- Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral
September 8, 2011
- CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 7, 2011
- MHLW Senior Vice Minister Tsuji, Parliamentary Secretary Fujita in Charge of Medical, Nursing Fee Revision
September 7, 2011
- Dr Kondo of PMDA Presents Example of Successful Use of Regulatory Science
September 6, 2011
- Pharmaceutical Industry Fully Sufficient as Export Industry: METI Minister Hachiro
September 5, 2011
- MHLW Minister Komiyama to Focus on Social Security Reform
September 5, 2011
- Noda Cabinet: MHLW Vice Minister Komiyama Promoted to Minister
September 5, 2011
- Korosho to Apply for PIC/S Membership in Early FY2012: New CND Director Nakaigawa
September 5, 2011
- New EAD Director Kamata Supports Making Premium for New Drug Development Permanent
September 5, 2011
- METI to Establish New Company to Support Medical Tourism from Overseas
September 5, 2011
- Avastin Recommended for Approval for Breast Cancer
September 5, 2011
- Fingolimod Recommended for Approval
September 5, 2011
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…